Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
September 21, 2009
- GSK to Supply Relenza for 13.5 Mil. Persons
September 21, 2009
- Olmetec Ranked No. 1 among ARBs in MR Activity Assessment: So-net M3
September 21, 2009
- NHO to Standardize Healthcare Services Using Its Own Database
September 21, 2009
- Fukuoka Pref. to Start Model Project to Promote Use of Generics
September 21, 2009
- Norvasc Most Reliable Antihypertensive: Nextit Research
September 21, 2009
- Novartis to Conduct Clinical Trial for Flu Vaccine in Japan
September 21, 2009
- Eli Lilly Japan to Achieve Sales of US$1 Bil. This Year
September 21, 2009
- NEW PRODUCTS
September 21, 2009
- ESC Congress in Barcelona
September 21, 2009
- R&D NEWS IN BRIEF
September 21, 2009
- NDA Review Time Shortened in 2008 but Still Far from Target
September 21, 2009
- Korosho Eliminates Redundancies from All-Patient Surveys and EPPV
September 21, 2009
- REGULATORY NEWS IN BRIEF
September 21, 2009
- Bristol-Myers Renews Website
September 21, 2009
- Drug Sales & Marketing System Needs "Systematic Throwback": Mr Kadonaga
September 14, 2009
- Survey Shows Large Regional Gaps in Respiratory Medical Services
September 14, 2009
- BUSINESS NEWS IN BRIEF
September 14, 2009
- Nearly 70% of Local Gov't-Managed Hospitals Operate in the Red
September 14, 2009
- Novartis Ranked No. 1 in Oncology: Cancer Patient Survey
September 14, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…